

WORLD HEALTH ORGANIZATION

ORGANISATION MONDIALE DE LA SANTE

WHO/CDS/CPE/GBUI/2000.2 Distr.: General Original: English

REPORT

3rd WHO Advisory Group Meeting on Buruli ulcer

1–3 March 2000 WHO Headquarters, Geneva

CONTENT

INTRODUCTION

RECOMMENDATIONS

Group 1: Research priority areas	7
Group 2: Surveillance, surveys and estimation of disease burden	8
Group 3: Drug treatment	12
Group 4: Training	14

ABSTRACTS

GBUI : History of an initiative Dr Mario Raviglione	16
GBUI : Plan of work for 2000 Dr Kingsley Asiedu	18
Buruli ulcer control efforts in the African Region Dr Eugene Nyarko	19
Discussion paper, clinical manifestations of <i>Mycobaterium ulcerans</i>	
Dr John Hayman	22
Summary activities carried out in 1999 for Buruli ulcer control in Benin Dr Augustin Guédénon	24
Monitoring report from Benin Dr Augustin Guédénon	28
Situation of Buruli ulcer control in Côte d'Ivoire Prof. Jean-Marie Kanga, Dr Djatch Edgard Kacou	31
Early detection and treatment of Buruli ulcer Prof. Jean-Marie Kanga	33
<i>Mycobacterium ulcerans</i> infection in French Guyana, the situation at 19 february 2000	
Dr Roger Pradinaud	37
Update on Buruli ulcer situation in Ghana Dr George K. Amofah	39

4

Mycobacterium ulcerans in Papua New Guinea Sister Joseph	47
Report from Togo Drs Napo Tignokpa and Battista G. Priuli	50
Update on research report from Australia Dr Paul Johnson, Dr Tim Stinear, Dr Travis Gooding, Mrs May Smith, Dr John Hayman, Dr John Davies, Dr Andrew Kemp, Dr Roy Robins- Browne, Ms Frances Oppedisano, Dr Diane Campbell et al.	52
Progress report on experimental chemotherapy of <i>Mycobacterium ulcerans</i> infection in the mouse model <i>Prof. Jacques Grosset, Hervé Dega, Nacer Lounis and Abdelhalim</i> <i>Bentoucha</i>	55
Update on research work form the Rocky Mountain Laboratory, Hamilton, Montana, USA <i>Dr Pamela Small</i>	59
Role of Centers for Disease Control and Prevention, Atlanta, USA Dr Jordan Tappero	61
Serodiagnosis of Buruli ulcer disease Dr C. Harold King	62
Buruli ulcer (<i>Mycobacterium ulcerans</i> infection) Dr Wayne Meyers, Sister Julia Aguiar, Prof. Françoise Portaels	64
Gamma interferon response to stimulation with <i>M. ulcerans</i> antigen preparations of peripheral blood T cells from patients with <i>M. ulcerans</i> disease	
Drs Harry Thangaraj, Mark Evans, Richard Phillips, Mr Joseph Adomako, Mr Nasas Ofosu-Kwabi, Prof. Ohene Adjei and Dr Mark Wansbrough-Jones	74
Conceptual problems in estimating the burden of Buruli ulcer Mr Frank Dadzie	75
Message from Professor Asano, Chancellor, Nippon Medical School, Tokyo, Japan, to the 3 rd annual meeting of the WHO advisory group on Buruli ulcer	
Dr Mwanatambwe Milanga	85
Role of Noguchi Memorial Institute for Medical Research, Accra, Ghana Prof. David Ofori-Adjei	87
Sasakawa Memorial Health Foundation, Tokyo, Japan Mrs Kay Yamaguchi	89

Case management of patients at the specialized center in Lalo, Mono department, Benin, Médecins sans Frontières Luxembourg's activities in	
Benin Drs Antoinette Kapinga, Pierre Humblet, and Christian Johnson	02
Dis Antoinette Kapinga, Fierre Humblet, and Christian Johnson	92
Contribution of the Kobe International University,	
Making of a new option to the Worldwide Movement for the Children of	
Buruli Ulcer: a case of Kobe International University	
Prof. Yuki Shimomura	98
Social mobilisation for Buruli ulcer	
Dr Elil Renganathan	101
ANNEXES	
	105
Annex 1: Agenda	105
Annex 2: List of participants	108

INTRODUCTION

Background

Mycobacterium ulcerans infection (Buruli ulcer) has rapidly emerged as an important cause of human morbidity around the world. The following countries have reported or suspected cases to date: **Africa:** Angola, Benin, Burkina Faso, Cameroon, Congo, Côte d'Ivoire, Democratic Republic of Congo, Equatorial Guinea, Gabon, Ghana, Guinea, Liberia, Nigeria, Sierra Leone, Togo, Uganda, Sudan; **Americas:** Bolivia, French Guiana, Mexico, Peru, Suriname **Asia:** China, India, Indonesia, Malaysia, Sumatra and **Western Pacific:** Australia, Kiribati, Papua New Guinea.

Buruli ulcer is the third most common mycobacterial disease of non-immunocompromised persons after tuberculosis and leprosy. The mode of transmission is not known. The disease generally affects impoverished inhabitants of remote rural areas with limited access to modern medical care. Most patients present late to the health services. About 70% of those affected are children under the age of 15 years. Buruli ulcer often starts as a painless nodule, which if left untreated, frequently leads to massive skin ulceration followed by debilitating complications. Currently, surgery is the treatment of choice but there are several limitating factors including: 1) inadequate surgical facilities in rural areas in the developing world; 2) high treatment costs; 3) recurrences after surgical treatment; and 4) the risk of transmission of infections such as HIV during surgery. Unfortunately, treatment with antibiotics has thus far been disappointing. The current social and economic burden imposed by Buruli ulcer on patients, their families and the health services is considerable.

In response to the growing spread and impact of Buruli ulcer, the World Health Organization (WHO) in 1998 established the Global Buruli Ulcer Initiative (GBUI) with the aims of raising awareness about this disease, mobilizing support to assist affected countries to deal with the disease, promoting and coordinating research, and coordinating the work of nongovernmental organizations (NGOs) and other partners. In February 1998, the first meeting of the Task Force (now called Advisory Group) consisting of some selected members was held in Geneva. A full membership of the Advisory Group has now been established consisting of 16 people whose expertise covers clinical and surgical intervention, epidemiology and research. The second meeting of this group was held in March 1999 in Geneva.

Objectives of the meeting

- 1. To define the research agenda for Buruli ulcer;
- 2. To define modalities for surveillance, surveys and estimation of the burden of the disease;
- 3. To define modalities for the use of drugs for the prevention of recurrences; and
- 4. To define training needs for Buruli ulcer.

Expected outcome

Recommendations to guide WHO's work on Buruli ulcer in the areas outlined in the objectives.

Welcome remarks

Dr David Heymann, Executive Director, Communicable Diseases welcomed and thanked all participants for attending the meeting. He presented an update on the reorganization at the WHO. The Buruli ulcer activity is now under the Department of communicable Disease Prevention and Control. He reiterated WHO's commitment to the Buruli Ulcer Initiative. He thanked The Nippon Foundation for providing financial support to the Initiative since its establishment in 1998 and also for the recent commitment to provide funds to cover Buruli ulcer activities up to 2002. He also thanked other partners who have joined the efforts to deal with the Buruli ulcer as a public health problem.

Dr Heymann emphasized the importance of obtaining the epidemiological and economic data needed to justify the efforts we are all putting into the disease. He stressed the need to find drug treatment for the disease given the problems associated with surgical treatment. In his concluding remarks, he was optimistic that the meeting will yield the recommendations needed to accelerate global efforts to fight the disease and wished the participants a successful meeting.

Dr Maria Neira, Director of the Department of Communicable Diseases Prevention and Control presented an overview of the Department's activities. She stressed the need to integrate some of the activities of various disease control activities. Through such collaborations, more can be achieved with the same resources. Dr Neira officially launched the WHO monograph on Buruli ulcer.

RECOMMENDATIONS

Group 1 – Research priority areas

1. Establish a Web Page: Global Buruli ulcer site (moderator: Kingsley Asiedu)

Purpose:

- encourage collaboration
- names
- list of current projects
- link with: 1. the Institute of Tropical Medicine, Antwerp 2. list of publications (Medline)

Newsletter (John Hayman)

2. Genome sequencing

Sanger center/St George's Hospital, Welcome Trust/WHO (*Jacques Grosset & Mark Wansbrough-Jones*)

- **3. Reference culture collection** All cultures to be sent to Institute of Tropical Medicine, Antwerp, Belgium (*Françoise Portaels*)
- 4. Tissue repository at AFIP, Washington DC, USA (Wayne Meyers)
- 5. Establishment of collaborating centres to support research and training (*WHO*)
- 6. Artificial ecosystems (different centres)
- 7. Human response to infection Serological response—serum bank (*Harold King*) Cell mediated response Vaccine development: avirulent live vaccine
- 8. Gene expression library
- **9.** Development of finger-printing system (based on PCR, as in TB) HLA susceptibility

预览已结束,完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 30491